Fair Value Measurements - Additional Information (Details)				1 Months Ended	3 Months Ended							6 Months Ended			12 Months Ended
	Mar. 27, 2017 USD ($)	Jan. 03, 2017 USD ($)	Dec. 18, 2013	Jan. 31, 2016 USD ($)	Jul. 01, 2017 USD ($)	Dec. 31, 2016 USD ($)		Oct. 01, 2016 USD ($)	Jul. 02, 2016 USD ($)	Apr. 02, 2016 USD ($)	Dec. 31, 2015	Jul. 01, 2017 USD ($) segments	Oct. 03, 2016	Jul. 02, 2016 USD ($)	Dec. 31, 2016 USD ($)		May 01, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Finite-lived intangible assets					$ 4,573,700,000	$ 4,417,200,000						$ 4,573,700,000			$ 4,417,200,000
Fair Value, Assets, Level 1, Level 2, Level 3 Transfers, Amount				$ 0	0							0
Net gain on reduction of contingent consideration												$ 15,600,000
Number of reporting units | segments												7
Average growth rate											(3.40%)		(2.00%)
Change in financial asset					38,700,000	(1,100,000,000)		$ 377,400,000	$ 910,800,000	$ 204,400,000		$ 21,600,000		$ 1,115,300,000
Royalty stream discrete period												20
Goodwill impairment charge										$ 130,500,000
Senior notes					3,234,300,000	5,373,100,000						$ 3,234,300,000			5,373,100,000
Proceeds from sale of business and other assets												37,200,000		$ 0
Measured at fair value on a non-recurring basis: | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Definite-lived intangible assets(3)					11,500,000	758,000,000	[1]					11,500,000			758,000,000	[1]
Definite lived asset impairment												19,600,000
RX
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Finite-lived intangible assets					0							0
Definite lived asset impairment					18,500,000
Proceeds from sale of business and other assets		$ 15,000,000
Specialty Sciences [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain on sale of unit	$ 17,100,000
CHCI
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Finite-lived intangible assets						2,300,000,000									2,300,000,000
Omega | Brands
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Definite lived asset impairment															1,500,000,000
Elan
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Effective date of acquisition			Dec. 18, 2013
Public Bonds and Private Placement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Senior notes					2,600,000,000	4,600,000,000						2,600,000,000			4,600,000,000
Public Bonds and Private Placement | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of fixed-rate long-term debt					2,700,000,000	4,600,000,000						2,700,000,000			4,600,000,000
Retail Bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long term debt					634,300,000	773,100,000						634,300,000			773,100,000
Unamortized debt premium					40,200,000	49,800,000						40,200,000			49,800,000
Retail Bonds | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of fixed-rate long-term debt					$ 682,700,000	825,000,000						$ 682,700,000			$ 825,000,000
Tysabri®
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percent of royalty revenues generated by specific agreement																	12.00%
Minimum | Tysabri®
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percent of royalty revenues generated by specific agreement															18.00%
Net sales															$ 2,000,000,000
Maximum | Tysabri®
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percent of royalty revenues generated by specific agreement															25.00%
Net sales															$ 2,000,000,000
Goodwill | Minimum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate															7.00%
Long-term growth rates															2.00%
Goodwill | Maximum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate															14.50%
Long-term growth rates															3.00%
Royalty Pharma
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Sale price of divestiture - cash plus non-cash	2,850,000,000
Proceeds from sale of business and other assets	2,200,000,000
Proceeds from sale of business, maximum milestone payments in year two	250,000,000
Proceeds from sale of business, maximum milestone payments in year four	$ 400,000,000
Volatility rate												30.00%
Rate of return												8.05%
Royalties receivable						$ 84,400,000									$ 84,400,000

[1] (3) As of July 1, 2017, definite-lived intangible assets with a carrying amount of $31.1 million were written down to a fair value of $11.5 million, resulting in a total impairment charge of $19.6 million. As of December 31, 2016, definite-lived intangible assets with a carrying amount of $2.3 billion were written down to a fair value of $758.0 million, resulting in a total impairment charge of $1.5 billion. Included in this balance are indefinite-lived intangible assets with a fair value of $364.5 million and $674.2 million that were reclassified to definite-lived assets at April 3, 2016 and October 2, 2016, respectively.